NCT07218341

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Conditions

• Chronic Lymphocytic Leukemia
• Lymphoma, Small Lymphocytic

Interventions

Type	Name	Description
DRUG	Pirtobrutinib	Administered orally
DRUG	Idelalisib	Administered orally

Timeline

• Start date: 2026-03-09
• Primary completion: 2030-05-01
• Completion: 2032-12-01
• First posted: 2025-10-20
• Last updated: 2026-04-17

Locations

53 sites across 16 countries: United States, Australia, Austria, Belgium, Canada, China, Croatia, Czechia, France, Hungary, Ireland, Italy, Japan, Poland, Spain, United Kingdom

Regulatory

• FDA-regulated drug study